New Delhi: The initial public offering (IPO) of Bain Capital-backed Emcure Pharmaceuticals Ltd was subscribed 67.87 times on the last day of the offer on Friday amid enthusiastic participation from institutional buyers.
According to NSE data, bids were received for 92,99,97,390 shares against 1,37,03,538 shares in the initial share sale.
The qualified institutional buyers (QIB) category was subscribed 195.83 times, while the non-institutional investors category was subscribed 48.32 times, and the retail individual investors (RII) quota was subscribed 7.21 times.
The company has fixed the price band of Rs 960-1,008 per share for the IPO.
The IPO comprises issuance of fresh equity shares worth Rs 800 crore and offer for sale (OFS) of 1.14 crore equity shares worth Rs 1,152 crore by promoters and existing shareholders at the upper end of the price band.
This takes the total public size to Rs 1,952 crore.
Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, a subsidiary of US-based private equity major Bain Capital.
Currently, Satish Mehta holds 41.85 percent stake in the company, and BC Investments holds 13.07 percent.
The proceeds from the fresh issue will be used for repayment of debt and general corporate purposes.
Emcure Pharmaceuticals on Tuesday said it has raised Rs 583 crore from anchor investors.
Pune-based firm Emcure Pharmaceuticals is engaged in the development, manufacturing and global marketing of a wide range of pharmaceutical products across several key therapeutic areas.
Kotak Mahindra Capital Company, Jefferies India, Axis Capital and JP Morgan India are the book-running lead managers to the issue.
The company's shares will be listed on BSE and NSE.
According to NSE data, bids were received for 92,99,97,390 shares against 1,37,03,538 shares in the initial share sale.
The qualified institutional buyers (QIB) category was subscribed 195.83 times, while the non-institutional investors category was subscribed 48.32 times, and the retail individual investors (RII) quota was subscribed 7.21 times.
The company has fixed the price band of Rs 960-1,008 per share for the IPO.
The IPO comprises issuance of fresh equity shares worth Rs 800 crore and offer for sale (OFS) of 1.14 crore equity shares worth Rs 1,152 crore by promoters and existing shareholders at the upper end of the price band.
This takes the total public size to Rs 1,952 crore.
Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, a subsidiary of US-based private equity major Bain Capital.
Currently, Satish Mehta holds 41.85 percent stake in the company, and BC Investments holds 13.07 percent.
The proceeds from the fresh issue will be used for repayment of debt and general corporate purposes.
Emcure Pharmaceuticals on Tuesday said it has raised Rs 583 crore from anchor investors.
Pune-based firm Emcure Pharmaceuticals is engaged in the development, manufacturing and global marketing of a wide range of pharmaceutical products across several key therapeutic areas.
Kotak Mahindra Capital Company, Jefferies India, Axis Capital and JP Morgan India are the book-running lead managers to the issue.
The company's shares will be listed on BSE and NSE.